Rates, predictors and mortality of sepsis-induced acute kidney injury: systematic review and meta-analysis

CURRENT STATUS: UNDER REVIEW

BMC Nephrology  BMC Series

Jie feng Liu
Central South University Xiangya School of Public Health

Hebin Xie
Science and education departent of Changsha central hospital

Ziwei Ye
Xiangya school of public health ,central south university

Lesan Wang
Xiangya school of public health

wlshncs@126.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-6819-5479

DOI:
10.21203/rs.3.rs-18145/v1

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
acute kidney injury, sepsis, risk factor, meta-analysis, systematic review
Abstract
Background The incidence and mortality of sepsis-induced acute kidney injury is high. Many studies have explored the causes of sepsis-induced acute kidney injury (AKI). However, its predictors are still uncertain; additionally, a complete overview is missing. A systematic review and a meta-analysis were performed to determine the predisposing factors for sepsis-induced AKI.

Method A systematic literature search was performed in the Medline, Embase, Cochrane Library, PubMed and Web of Science databases, with an end date parameter of May 25, 2019. Valid data were retrieved in compliance with the inclusion and exclusion criteria.

Result Forty-seven observational studies were included for analysis. A cumulative number of 55911 sepsis patients were evaluated. The incidence of AKI caused by septic shock is the highest. 30 possible risk factors were included in the meta-analysis. The results showed that 20 factors were found to be significant. The odds ratio (OR), 95% confidence interval (CI) and Prevalence of the most prevalent predisposing factors for sepsis-induced AKI were as the following: Septic shock[2.88(2.36-3.52), 60.47%], Hypertension[1.43(1.20-1.70), 38.39%], Diabetes mellitus[1.59(1.47-1.71), 27.57%], Abdominal infection[1.44(1.32-1.58), 30.87%], Vasopressors use[2.95(1.67-5.22), 64.61%], vasoactive drugs use [3.85(1.89-7.87), 63.22%], Mechanical ventilation[1.64(1.24-2.16), 68.00%], Positive blood culture[1.60(1.35-1.89), 41.19%], Smoke history[1.60(1.09-2.36), 43.09%]. Other risk factors include cardiovascular, coronary artery disease, liver disease, unknown infection, diuretics use, ACEI or ARB, gram-negative bacteria and organ transplant.

Conclusion A large number of factors are associated with AKI development in sepsis patients. Our review can guide risk-reducing interventions, clinical prediction rules, and patient-specific treatment and management strategies for sepsis-induced acute kidney injury.

Highlights

Highlights of this article
1. this the first systematic review and meta-analysis of risk factors for AKI development in sepsis patients.

2. Forty-seven observational studies were included for analysis. A cumulative number of 55911 sepsis...
patients were evaluated.

3. Thirty-one possible risk factors were included in the meta-analysis. The results showed that twenty factors were found to be significant. In addition, we have summarized the prevalence of these factors in sepsis who developed acute kidney injury.

**Background**

Sepsis-associated acute kidney injury (S-AKI) is a major public health problem. S-AKI is a syndrome of acute impairment of function and organ damage linked with long-term adverse outcomes depending on the extent of acute injury superimposed on underlying organ reserve. Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients and is associated with 40–50% of AKI patients. Importantly, S-AKI is strongly associated with poor clinical outcomes. Mortality in patients with sepsis complicated by AKI is significantly higher than in non-AKI patients. Among critically ill patients with AKI, S-AKI have a higher risk of in-hospital death and longer hospital stay than AKI caused by any other cause. Despite recent advances in medicine and surgery, its morbidity have not declined. Mounting evidence suggests that AKI incidence is increasing. In a large 10-year cohort that included more than 90,000 patients from more than 20 ICUs, AKI incidence increased by 2.8% per year. Moreover, With the global aging trend, and the majority of sepsis patients are mainly elderly, the number of patients with sepsis-induced AKI may continue to increase. Sepsis-associated AKI portends a high burden of morbidity and mortality in both children and adults with critical illness. Unfortunately, the Pathogenesis of S-AKI is still not completely clear. There are also many difficulties in the early diagnosis and treatment of S-AKI. Therefore, the early identification of risk factors and prevention of S-AKI is extremely important. Unfortunately, a number of studies have explored the risk factors for AKI development in sepsis patients, but few studies have yielded relatively consistent results. Because of the inconsistency of diagnostic criteria of sepsis and AKI and regional differences, the application of the research results obtained is controversial and limited. However, there still has not been a study published for systematic review and meta-analysis on this topic. The aim of this work was to systematically review and meta-analyses the evidence on the association between sepsis
and AKI in cohort and case-control studies.

Methods

**Inclusion Criteria**

We selected all studies that met the following criteria:
1. Patients older than 16 years with a hospitalization stay of greater than 24 hours
2. Studies were able to extract data from the 2×2 contingency table
3. Sepsis and septic shock was diagnosed by the Internationally recognized standards in the original study, such as sepsis 1.0, sepsis2.0, sepsis3.0.
4. Acute kidney injury was diagnosed by the Internationally recognized standards, such as KDIGO, AKIN and RIFLE.
5. Studies had a cohort or case-control design and patients were grouped into sepsis AKI and sepsis non-AKI.

**Data Sources and Search Strategy**

A systematic review and meta-analysis of scientific peer-reviewed literature was performed; the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline were followed for this report.

The systematic literature search was performed in the Medline, Embase, Cochrane Library, PubMed and Web of Science databases from inception to the June 2019 with no restrictions, for studies that assessed the risk of AKI development in sepsis patients. Following search terms were used and combined: (septic OR sepsis OR severe sepsis OR Septicemia OR septic shock OR sepsis-induced OR sepsis-associated) AND (Acute Kidney Injury OR Acute Renal Injury OR Acute Renal Insufficiency OR AKI OR acute renal failure OR ARF). A manual search on the reference lists of included articles was also carried out. Gray literature (generally refers to nonpublicly published literature) and conference abstracts were not searched.

**Data Extraction**

Two independent reviewers participated in the entire process of literature retrieval. First, the titles and abstracts of the retrieved literature are analyzed to exclude irrelevant studies. After that, full-text analysis is performed by the inclusion/exclusion criteria. Data extraction was performed using a standardized data collection form. Data collected included:
1. study characteristics: publication year, study design, country of origin, sepsis and acute kidney injury diagnostic criteria, sepsis type, period of data report.

2. number of the 2×2 contingency table and unadjusted crude odds ratios with regard to demographic data (gender) and investigated independent variables/predictors (comorbidities, source of infection, medication, Invasive treatment, sepsis types and blood culture)

3. outcome: the primary endpoint will be S-AKI, the Secondary outcome was prevalence of influence factors and mortality in patients of S-AKI.

**Quality Assessment**

Study selection, data extraction, and quality assessment were independently performed by two authors. Any disagreements are resolved through discussions between authors until a consensus is reached. If disagreements persisted, they were solved by a third reviewer. Quality assessment for the observational studies included in the meta-analysis was performed using the Newcastle-Ottawa scale (available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).

**Statistical Analysis**

The core characteristics of the study and patients were sorted out and summarized through Microsoft Office Excel 2010. The frequency distribution is expressed as a percentage. For the meta-analysis, we only used unadjusted crude odds ratios from ≥3 studies (OR) to standardize the results because of the wide variability of multivariable models across studies. We used Stata/SE version11 for statistical analyses and a two-sided P value of 0.05 or less to indicate statistical significance. Heterogeneity among studies was evaluated by calculating the I² statistic (significance level at I²>50%) and chi-square test (significance level at P≤0.10). We categorized I² of <25%, 25% to 75%, and >75% as corresponding to low, moderate, and high between trial heterogeneity, respectively. If severe heterogeneity was present at I² >50%, the random effect models were chosen, otherwise the fixed effect models were used. For results with a heterogeneity of less than 50% and a fixed-effects model, we will explore its stability by transforming into a random effects model. Meta regression and subgroup analyses (≥6 studies) would be conducted according to publication year, study design,
country of origin, sepsis type and diagnostic criteria of acute kidney injury and sepsis, if heterogeneity among studies was high ($I^2>50\%$ and $P<0.10$). We conducted a sensitivities analysis ($\geq3$ studies) on the overall risk estimate by omitting 1 study in each turn, to estimate whether the results could have been affected markedly by a single study. We explored publication bias by examining funnel plots visually, and using the Egger test for asymmetry for those risk factors with pooled data from $\geq7$ studies.

**Results**

1. **Literature search** *(Figure 1)*

8033 records from the Medline, Embase, Cochrane Library, PubMed and Web of Science databases were initially identified. After filtering by title and abstract, most of them are excluded due to the duplicate, review, or unrelated topic. After 626 studies were reviewed in full text, 579 articles were excluded according to review and comments papers, inconsistent control settings, unknown AKI or sepsis diagnostic criteria, special population, duplicate and limited data. Finally, 47 articles including 22 sepsis, 12 septic shock, 5 severe sepsis and 8 others met the inclusion criteria and were conducted systematic review and meta-analysis.

2. **Characteristics of Included Studies** *(table 1)*

The characteristics of the included articles are shown in table 1. Studies were published between 2008 and 2019, and were from eighteen countries (Spain, Greece, United Kingdom, France, Netherlands, Sweden, Canada, United States, Brazil, China, Japan, Saudi Arabia, Turkey, Finland, Portugal, South Korea and Australia) on four continents (Europe, America, Asia and Oceania). All studies were observational including 12 retrospective cohorts, 25 prospective cohorts and 12 case-control studies. A total of 55911 sepsis patients were included in the analysis. Document quality assessment shows that the methodological quality of all studies is high, achieving a quality score of $\geq6$ of 8.

3. **Summary data from included studies** *(table 2)*

This study summarized the characteristics of sepsis patients who developed AKI. ICU mortality, hospital mortality, 28-day mortality and 90-day mortality of S-AKI were respectively reported at
45.99% (1989/4325) in 15 studies, 49.84% (2732/5481) in 10 studies, 36.67% (161/439) in 4 studies, 64.66% (2406/3721) in 5 studies. The 90-day mortality is the highest. In S-AKI patients, all mortality rates of AKI caused by septic shock are the highest, while that caused by severe sepsis was the lowest.

Regarding comorbidities, the most common one is ARDS (47.02%, 489/1040, from 3 studies), followed by hypertension (38.39%, 3263/8500, from 32 studies), diabetes (27.57%, 2248/8155, from 32 studies) and stroke (22.79%, 67/294, from 4 studies). Cirrhosis and Liver disease were the least common and account for only (4.71%, 99/2104, from 6 studies) and (3.74%, 554/14081, from 7 studies). Hepatic failure in sepsis were more common in sepsis than in septic shock and severe sepsis. Hypertension in septic shock is less common than sepsis and severe sepsis (26.16% VS 42.28% and 58.07%), while Chronic kidney disease was more prevalent (45.13% VS 15.52% and 11.02%). Hypertension and diabetes were more prevalent in severe sepsis than in sepsis and septic shock (58.7% VS 42.28% and 26.16%, 30.20% VS 20.53% and 26.75%).

On admission, patient mainly comes from emergency admission (50.88%, 9235/18149, from 8 studies) and medical admission (47.02%, 8701/18506, from 7 studies), followed by operative admission and surgical ward. In the use of Medications, vasoactive drugs are the most commonly used drugs, accounting for 64.61% (1293/2001, from 5 studies), and vasopressors among vasoactive drugs is the most frequently used, accounting for 63.22% (911/1441, from 7 studies), followed by steroids, diuretics, ACEI or ARB, stains and NSAIDS. vasoactive drugs and vasopressors were more prevalent in septic shock and severe sepsis than in sepsis.

Six sources of infection were reported in this study, with the order of occurrence rate from high to low being the following: pulmonary (46.05%, 1480/3214, from 19 studies), respiratory (32.08%, 85/273, from 7 studies), abdominal (30.87%, 2152/6971, from 25 studies), Urinary tract (11.14%, 630/5653, from 19 studies), skin or soft tissue (6.03%, 335/5554, from 13 studies), unknow (6.02%, 100/1662, from 4 studies).

Community acquired infection was reported in 3 studies at 57.36% (2041/3558), which was higher than nosocomial acquired infection reported in 2 studies at 39.81% (2474/6215). Twenty-four studies
reported mechanical ventilation in 68.00% (7167/10539, from 24 studies), and mechanical ventilation in septic shock and severe sepsis was more prevalent than in sepsis. Other prevalent factors include positive blood culture (41.38%,3259/7876, from 8 studies), Smoke history (43.09%,642/1490, from 5 studies).

4. Risk Factor Analysis of AKI

Comorbidities

Hypertension was pooled from 32 studies with a significant (OR,1.43;95%CI:1.20-1.70), moderate heterogeneity($I^2=74.00\%$). Sources of heterogeneity were not identified using subgroup analysis. The results of the sensitivity analysis are consistent. After 3 studies with heterogeneity is excluded, the heterogeneity decrease and the result remains stable.

Diabetes mellitus was pooled from 32 studies with a significant (OR 1.59;95%CI:1.47-1.71), moderate heterogeneity($I^2=37.1\%$). The results are still stable after using the random effects model.

Chronic kidney disease was pooled from 14 studies with a significant (OR,3.49;95%CI:2.36-5.15), moderate heterogeneity($I^2=71.70\%$). Sources of heterogeneity were not identified using subgroup analysis. The results of the sensitivity analysis are consistent. After a study with heterogeneity is excluded, the heterogeneity among studies was reduced to low heterogeneity (25.6%) and the result remains stable.

Cardiovascular disease (from 14 studies, OR,1.31;95%CI:1.24-1.40), liver disease (from 17 studies, OR, 1.68;95%CI: 1.47-1.90) were all low heterogeneity and identified as risk factors. Their results are still stable after using the random effects model.

Coronary artery disease was pooled from 8 studies with a significant (OR,1.27;95%CI:1.08-1.49), moderate heterogeneity($I^2=37.1\%$). The results are still stable after using the random effects model.

Source of infection

Pulmonary infection was pooled from 8 studies with a significant (OR,0.77;95CI:0.60-0.99), moderate heterogeneity ($I^2 = 77.60\%$). Sources of heterogeneity were not identified using subgroup analysis. The results of the sensitivity analysis are consistent.
Abdominal infection was pooled from 25 studies with a significant (OR,1.44; 95%CI:1.32-1.58), moderate heterogeneity ($I^2 = 40.20\%$). The results of the sensitivity analysis are consistent. After a study with heterogeneity is excluded, the heterogeneity disappears and the result remains stable. The results are still stable after using the fixed effects model.

Unknow infection was pooled from 25 studies with a significant (OR,2.01;95CI:1.35-2.98), low heterogeneity($I^2=0\%$). The results are still stable after using the random effects model.

**Medications**

Vasoactive drugs were pooled from 5 studies with a significant (OR,3.85;95%CI:1.89-7.87), high heterogeneity ($I^2=86.40\%$). After a study with heterogeneity is excluded, the heterogeneity disappears and the result remains stable. The results of the sensitivity analysis are consistent. 

Vasopressors (from 7 studies, OR, 3.15;95%CI: 2.00-4.96) and ACEI or ARB (from 8 studies, OR,1.61;95%CI:1.10-2.36) were all high heterogeneity($I^2\geq75\%$) and identified as risk factors. Sources of heterogeneity were not identified using subgroup analysis and their results of the sensitivity analysis are stable.

Diuretics was pooled from 5 studies with a significant (OR,1.40;95%CI:1.13-1.72), low heterogeneity($I^2=0\%$). The results are still stable after using the random effects model.

**Other factors**

Male sex was pooled from 43 studies with a significant (OR,1.22;95%CI:1.06-1.40), moderate heterogeneity($I^2=69.80\%$). Sources of heterogeneity were not identified using subgroup analysis. The results of the sensitivity analysis are consistent.

Gram-negative bacteria (from 3 studies, OR, 2.19;95%CI:1.52-3.15) and organ transplant (from 3 studies, OR,1.96;95%CI:1.48-2.61) were all low heterogeneity($I^2=0\%$) and identified as risk factors. Their results are still stable after using the random effects model.

Mechanical ventilation was pooled from 24 studies with a significant (OR,1.64;95%CI:1.24-2.16), high heterogeneity ($I^2=88.70\%$). Sources of heterogeneity were not identified using subgroup analysis. he
results of the sensitivity analysis are consistent.

Positive blood culture was pooled from 9 studies with a significant (OR, 1.60; 95% CI: 1.35-1.89), moderate heterogeneity ($I^2 = 50.20\%$). Sources of heterogeneity were not identified using subgroup analysis. The results of the sensitivity analysis are consistent.

Smoke history was pooled from 5 studies with a significant (OR, 1.60; 95% CI: 1.09-2.36), high heterogeneity ($I^2 = 78.30\%$). The results of the sensitivity analysis are consistent. After a study with heterogeneity is excluded, the heterogeneity disappears and the result remains stable.

Organ transplant was pooled from 3 studies with a significant (OR, 1.96; 95% CI: 1.48-2.61), low heterogeneity ($I^2 = 0\%$). The results are still stable after using the random effects model.

5. Tests for Publication Bias

All risk factors (≥7 studies) of the egger’s rank correlation test and the Egger linear regression test indicated no evidence of publication bias except cardiovascular disease (P=0.015) (table 3). Smoke history, cirrhosis, multiorgan dysfunction (≥3) unknow site of infection, vasoactive drugs, diuretics and organ transplant were not performed test of public bias because of less number of studies (7 studies)

Discussion

Major Findings

To the best of our knowledge, this is the first meta-analysis providing comprehensive insights into the risk factors of AKI in sepsis patients. In total, 47 studies including 55911 sepsis patients were included. 46 factors were examined in systematic review and summarized. Among comorbidities present, the top three in terms of prevalence are ARDS, hypertension and diabetes mellitus; On admission, patient mainly comes from emergency admission and medical admission; Regarding sources of infection, the top three in terms of prevalence are pulmonary, respiratory and abdominal. vasopressors and vasoactive drugs were the most frequently used drugs in present S-AKI patients. Other prevalent factors include mechanical ventilation, community acquired infection, positive blood culture, and Smoke history. 31 factors were assessed with meta-analysis. The results showed that 20 factors were found to be significant. The odds ratio (OR), 95% confidence interval (CI) and Prevalence
of the most prevalent predisposing factors for sepsis-induced AKI were as the following: Septic shock[2.88(2.36-3.52), 60.47%], Hypertension[1.43(1.20-1.70), 38.39%], Diabetes mellitus[1.59(1.47-1.71), 27.57%], Abdominal infection[1.44(1.32-1.58), 30.87%], Vasopressors use[2.95(1.67-5.22), 64.61%], Vasoactive drugs use[3.85(1.89-7.87), 63.22%], Mechanical ventilation[1.64(1.24-2.16), 68.00%], Positive blood culture[1.60(1.35-1.89), 41.19%], Smoke history[1.60(1.09-2.36), 43.09%]. We also found that AKI caused by septic shock had the highest incidence and mortality among sepsis patients from included studies.

**Analysis of Risk Factor**

Risk factors for sepsis-associated AKI can be categorized as pre-sepsis, sepsis disease itself and sepsis-related treatment. As for the risk factors of pre-sepsis (eg, concurrent chronic diseases, sex, age, smoke history) and sepsis disease itself (eg, sepsis type, source of infection, infected bacteria), these existed before or when the sepsis was diagnosed, and are almost impossible to change. However, these factors can remind us that people with these factors are at high risk for AKI, so that we can take timely precautions such as reducing the occurrence of more risk factors in the future. The risk factors associated with sepsis-related treatment are things we can control and change (eg, medication, mechanical ventilation).

**1) Risk factors of pre-sepsis**

Our study showed many chronic diseases among comorbidities were associated with AKI development in sepsis patients. Hypertension and diabetes mellitus among comorbidities were the most common risk factor of AKI, other factors include Chronic kidney disease, cardiovascular, coronary artery disease and liver disease. This may be due to the fact that Sepsis patients include a large proportion of older adults aged 65 years and older. We found diabetes mellitus and hypertension increased the risk of AKI, which is consistent with other studies. Moreover, when AKI occurs in CKD patients, it is more severe and difficult to recover. There is increasing recognition that acute kidney injury (AKI) and chronic kidney disease (CKD) are closely linked and likely promote one another. However, The
association between severity of CKD (e.g., as measured by levels of estimated GFR) and risk of AKI has not been quantified until relatively recently. A meta-analysis showing that CKD increased risk of developing AKI in patients with diabetes or hypertension. Therefore, in addition to directly increasing the risk of AKI, diabetes mellitus, hypertension and CKD could also interact to promote the occurrence of AKI. In addition, these three factors are also prevalent risk factors of AKI, so we should pay more attention to patients with these three factors to reduce the incidence of AKI.

Whether gender is a risk factor for AKI is controversial, but our study found a slight association between AKI and male sex. A study found lower glomerular filtration rate (eGFR) and higher albuminuria (albumin-creatinine ratio [ACR]) were associated with higher AKI risk in both men and women, and male sex was associated with higher risk of AKI, with a slight attenuation in lower eGFR but not in higher ACR.

(2) Risk factors of sepsis disease itself

In our study, AKI caused by septic shock among sepsis patients had the highest incidence and mortality, and septic shock was also a significant risk factor for AKI, so more attention should be paid to the prevention of AKI in patients with septic shock.

The data summarized indicate that Pulmonary and abdominal infections are the most common source of infection for sepsis who developed AKI, both of them are also the most common risk factors for patients with sepsis. And our study also found that both are also associated with AKI development. Abdominal infections could increase risk of AKI development, but our study found that lung infection is a protective factor for AKI. At present, there is no research report on such results. Because of its high heterogeneity($I^2=77.6\%$), we conducted sensitivity analysis and subgroup analysis. The result of sensitivity analysis on the overall risk estimate were stable by recommending 1 study in each turn. The results of subgroup analysis showed that after grouping according to Chinese population and non-Chinese population, the heterogeneity of the two groups decreased, and pulmonary infection was a risk factor in Chinese population(OR,1.62;95%CI:1.06-2.49), but a protective factor in other populations (OR,0.61;95%CI:0.50-0.74). We are cautious about the overall results and the results of
subgroup analysis, because there is no reasonable explanation for this result and there is a great deal of heterogeneity. Further research on this phenomenon may be needed in the future.

The relationship between the occurrence of AKI and the infected bacteria has rarely been reported. Our study found that gram-negative bacteria are a risk factor for AKI. It is unclear which bacteria in Gram-negative bacteria are involved in AKI. Only one study showed that Escherichia coli may be associated with the development of AKI. More research may be needed to verify in the future.49

(3) Risk factors of sepsis-related treatment

In medication, our study found that vasoactive drugs, diuretics, vasopressors and ACEI or ARB are associated with the occurrence of AKI. Vasoactive drugs are commonly used in patients with sepsis, especially septic shock. Our research found that vasopressors increased the risk of AKI, whether other vasoactive drugs can cause this result is uncertain. A large cohort study (Mansfield et al., 2016) shows ACEI/ARB is associated with only a small increase in AKI risk while individual patient characteristics are much more strongly associated with the rate of AKI. Among patients with CKD, there is no increased risk of developing AKI compared with those who are not exposed to ACEI/ARB, while exposure to ACEI/ARB in people without CKD increases the risk of AKI. A multi-center prospective study in Shanghai showed that diuretics accounted for 22.2% of all drug-induced AKI, ranked only after antibiotics.68 Another study showed a triple therapy combination consisting of diuretics with ACEI or ARB and NSAIDs was associated with an increased risk of acute kidney injury.69 But it cannot be ignored that these factors have high heterogeneity, and we have not found the source of it, so we are cautious about these results. This part of heterogeneity may come from the specific types, duration and dosage of drugs and the interaction with other drugs. More homogeneous clinical randomized trials in sepsis patients should be conducted to confirm the role of these drugs and their interactions in inducing acute kidney injury.

At present, many studies have confirmed that mechanical ventilation was a risk factor for AKI, which were consistent with our result.70,71 A Study have shown that in patients in the intensive care unit, mechanical ventilation is used up to 75%.72 Our summary data shows that 68% of sepsis patients who
developed AKI used mechanical ventilation, which is even higher in patients with septic shock and severe sepsis. Therefore, we have to pay special attention to prevent the development of AKI in patients with mechanical ventilation. Hypoxemia, hypercapnia, and excessive PEEP values during mechanical ventilation are all risk factors for AKI. If there are other risk factors at the same time, AKI is more likely to occur. Now, there is no good measure to prevent or reduce the AKI caused by mechanical ventilation. Some studies have shown that the development of AKI can be reduced by adjusting ventilator parameters, improving hypoxia status as soon as possible, avoiding persistent hypercapnia, and using too little PEEP (positive end-expiratory pressure) value. However, a meta-analysis shows that invasive MV is associated with a threefold increase in odds of AKI in critically ill patients, and tidal volume (Vt) and PEEP settings do not see to modify the risk. Therefore, future research should focus on how to reduce AKI caused by mechanical ventilation.

Limitations

However, some limitations in our meta-analysis should be mentioned: (1) Our results were based on unadjusted estimates due to the wide variability of multivariable models across studies, which did not allow us to determine which factors are independent predictors of AKI because of the existence of confounding factors. (2) Significant heterogeneity was present for some risk factors because population-based studies encompassed different geographic locations, demographic data and inconsistent the diagnostic criteria of AKI and sepsis, but we have not found its source by using subgroup analysis, which may have an impact on our research results. In addition, part of the risk factors, due to the small number of studies, did not explore heterogeneity and publication bias.

Conclusion

The most common risk factors for S-AKI are as follows: septic shock, hypertension, diabetes mellitus, abdominal infection, smoke history, positive blood culture, vasopressors use, mechanical ventilation. Other risk factors include cardiovascular, coronary artery disease, liver disease, unknown infection, diuretics use, ACEI or ARB, gram-negative bacteria and organ transplant. Despite our rigorous methodology, the inherent limitations of included studies prevent us from reaching definitive conclusions. However, this the first systematic review and meta-analysis of risk factors for AKI.
development in sepsis patients, which can advance adoption of more evidence-based, targeted clinical care pathways for AKI prevention, detection, and management for sepsis patients.

Abbreviations
AKI acute kidney injury
S-AKI Sepsis-associated acute kidney injury
ARF Acute Renal failure
OR Odds ratio
CI Confidence interval
CKD Chronic kidney disease
KDIGO Kidney Disease Improving Global Outcomes
AKIN Acute kidney injury network classification
RIFLE Risk, injury, failure, end stage kidney disease
NSAIDs Non-steroidal anti-inflammatory drugs
COPD Chronic obstructive pulmonary disease
ACEI or ARB angiotensin converting enzyme inhibitors or Angiotensin Receptor Blocker
PEEP positive end-expiratory pressure

Declarations

Ethics approval and consent to participate
Not applicable.

Consent to publish
Not applicable.

Availability of data and materials
All data generated or analysed during this study are included in this published article [and its Additional files and Supplementary materials].

Competing interests
There is no conflict of interest in relation to this study.

Funding
This work was supported by Regular funded projects awarded to XHB from the Health Committee of Hunan Province.

The funders had no role in any stage of the design and conduct of the study, collection, management, analysis, and interpretation of data in the study, or the preparation, review, or approval of the manuscript.

**Author contributions**

LJF: study design, data collection, data analysis, writing; XHB: data collection, data analysis, writing; YZW: data collection, data analysis; WLS: study design, writing. all authors have read and approved the final manuscript.

**Acknowledgment**

Not applicable.

**Contributor Information**

Liujiefeng:201397@163.com
Xiehebin:248207294@qq.com
Yeziwei:yezuweiwriting@163.com
Wanglesan:wlshncs@126.com

**References**

1. Alobaidi R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-associated acute kidney injury. Semin Nephrol 2015;35: 2-11. doi 10.1016/j.semnephrol.2015.01.002.

2. Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11: R68. doi 10.1186/cc5949.

3. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney Net al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007;2: 431-439. doi 10.2215/CJN.03681106.
4. Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, Liang X, Fu P, Liu ZH, Mehta RL. A Prospective International Multicenter Study of AKI in the Intensive Care Unit. Clin J Am Soc Nephrol 2015;10: 1324-1331.

5. Hsu YC, Hsu CW. Septic acute kidney injury patients in emergency department: The risk factors and its correlation to serum lactate. Am J Emerg Med 2019;37: 204-208. doi 10.2215/CJN.04360514.

6. Clifford KM, Dy-Boarman EA, Haase KK, Maxvill K, Pass SE, Alvarez CA. Challenges with Diagnosing and Managing Sepsis in Older Adults. Expert Rev Anti Infect Ther.2016;14: 231-241. doi:10.1586/14787210.2016.1135052.

7. Rowe TA, McKoy JM. Sepsis in Older Adults. Infect Dis Clin North Am 2017;31: 731-742. doi:10.1016/j.idc.2017.03.006.

8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 2009; 6: e1000097. https://doi:10.1371/journal.pmed.1000097.

9. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. CHEST 1992; 101:1644-1655. doi:1378/chest.101.6.1644.

10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538. doi: 1097 / 01.CCM.0000050454.01978.3B.

11. Singer M, Deutschman C S, Seymour C W et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): p. 801-10. doi:10.1001 / jama.2016.0287.

12. Bu X, Zhang L, Chen P, Wu X. Relation of neutrophil-to-lymphocyte ratio to acute
kidney injury in patients with sepsis and septic shock: A retrospective study. Int Immunopharmacol 2019; 70:372-377. doi:10.1016/j.intimp.2019.02.043.

13. Hsu YC, Hsu CW. Septic acute kidney injury patients in emergency department: The risk factors and its correlation to serum lactate. Am J Emerg Med 2019; 37:204-208. doi:10.1016/j.ajem.2018.05.012.

14. Vilander LM, Vaara ST, Donner KM, Lakkisto P, Kaunisto MA, Pettila V. Heme oxygenase-1 repeat polymorphism in septic acute kidney injury. Plos One 2019; 14:e217291. doi:10.1371/journal.pone.0217291.

15. Xing ZQ, Liu DW, Wang XT, Long Y, Zhang HM, Wang C, Huang W. The value of renal resistance index and urine oxygen pressure for prediction of acute kidney injury in patients with septic shock. Zhonghua Nei Ke Za Zhi 2019; 58:349-354. doi:10.3760/cma.j.issn.0578-1426.2019.05.004.

16. Moman RN, Ostby SA, Akhhoundi A, Kashyap R, Kashani K. Impact of individualized target mean arterial pressure for septic shock resuscitation on the incidence of acute kidney injury: a retrospective cohort study. Ann Intensive Care 2018; 8:124. doi:10.1186/s13613-018-0468-5.

17. Zhi DY, Lin J, Zhuang HZ et al. Acute Kidney Injury in Critically Ill Patients with Sepsis: Clinical Characteristics and Outcomes. Journal of Investigative Surgery 2018;32:689-696. doi.org/10.1080/08941939.2018.1453891

18. Zhou X, Liu J, Ji X, Yang X, Duan M. Predictive value of inflammatory markers for acute kidney injury in sepsis patients: analysis of 753 cases in 7 years]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2018; 30:346-350. doi:10.3760/cma.j.issn.2095-4352.2018.04.012.

19. Costa NA, Gut AL, Azevedo PS, Tanni SE, Cunha NB, Fernandes A, Polegato BF, Zornoff L, de Paiva S, Balbi AL et al. Protein carbonyl concentration as a biomarker for
development and mortality in sepsis-induced acute kidney injury. Biosci Rep 2018; 38(1). doi:10.1042/BSR20171238.

20. Song J, Wu W, He Y, Lin S, Zhu D, Zhong M. Value of the combination of renal resistance index and central venous pressure in the early prediction of sepsis-induced acute kidney injury. J Crit Care 2018; 45:204-208. doi 10.1016/j.jcrc.2018.03.016.

21. Hu Q, Ren J, Ren H, Wu J, Wu X, Liu S, Wang G, Gu G, Guo K, Li J. Urinary Mitochondrial DNA Identifies Renal Dysfunction and Mitochondrial Damage in Sepsis-Induced Acute Kidney Injury. Oxid Med Cell Longev 2018; 2018:8074936. doi 10.1155/2018/8074936.

22. Fatani SH, ALreai AA, Al-Amodi HS, Kamel HF, Al-Khatieb K, Bader H. Assessment of tumor necrosis factor alpha polymorphism TNF-alpha-238 (rs 361525) as a risk factor for development of acute kidney injury in critically ill patients. Mol Biol Rep 2018; 45:839-847. doi 10.1007/s11033-018-4230-8.

23. Gameiro J, Goncalves M, Pereira M et al. Obesity, acute kidney injury and mortality in patients with sepsis: A cohort analysis. Ren Fail 2018, 40(1): 120-126. doi 10.1080/0886022X.2018.1430588.

24. Katayama S, Nunomiya S, Koyama K, Wada M, Koinuma T, Goto Y, Tonai K, Shima J. Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin. Crit Care 2017; 21 :229. doi 1186/s13054-017-1815-x.

25. Vilander LM, Kaunisto MA, Vaara ST, Pettila V. Genetic variants in SERPINA4 and SERPINA5, but not BCL2 and SIK3 are associated with acute kidney injury in critically ill patients with septic shock. Crit Care 2017; 21:47. doi 10.1186/s13054-017-1631-3.

26. Suberviola B, Rodrigo E, Gonzalez-Castro A, Serrano M, Heras M, Castellanos-Ortega A. Association between exposure to angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Intensiva 2017; 41:21-27. doi 10.1016/j.medin.2016.07.010.

27. Fisher J, Russell JA, Bentzer P, Parsons D, Secchia S, Morgelin M, Walley KR, Boyd JH, Linder A. Heparin-Binding Protein (HBP): A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury. Shock 2017; 48:313-320. doi 10.1097/SHK.0000000000000862.

28. Perez-Fernandez X, Sabater-Riera J, Ballus-Noguera J, Cardenas-Campos P, Moreno-Gonzalez G, Alonso-Juste V, Corral-Velez V, Gutierrez-Arambula D, Gumucio-Sanguino V, Betbese-Roig Aet al. No impact of surviving sepsis campaign care bundles in reducing sepsis-associated acute kidney injury. Clin Nephrol 2017; 88:105-111. doi 5414/CN109134.

29. Pereira M, Rodrigues N, Godinho I, Gameiro J, Neves M, Gouveia J, Costa ESZ, Lopes JA. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the 'Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease' (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Clin Kidney J 2017; 10 :332-340. doi 10.1093/ckj/sfw107.

30. Panich T, Chancharoenthana W, Somparn P, Issara-Amphorn J, Hirankarn N, Leelahavanichkul A. Urinary exosomal activating transcriptional factor 3 as the early diagnostic biomarker for sepsis-induced acute kidney injury. Bmc Nephrol 2017; 18:10. doi 10.1186/s12882-016-0415-3.

31. Su C M, Cheng H H, Hung C W et al. The value of serial serum cell adhesion molecules in predicting acute kidney injury after severe sepsis in adults[J]. Clin Chim Acta 2016; 457:86-91. doi 10.1016/j.cca.2016.04.008.

32. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Can neutrophil-lymphocyte ratio be
independent risk factor for predicting acute kidney injury in patients with severe sepsis? Ren Fail 2015; 37:225-229. doi 10.3109/0886022X.2014.982477.

33. Medeiros P, Nga HS, Menezes P, Bridi R, Balbi A, Ponce D. Acute kidney injury in septic patients admitted to emergency clinical room: risk factors and outcome. Clin Exp Nephrol 2015; 19:859-866. doi 10.1007/s10157-014-1076-9.

34. Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury. Crit Care 2015; 19:223. doi 10.1186/s13054-015-0941-6.

35. Sood M, Mandelzweig K, Rigatto C, Tangri N, Komenda P, Martinka G, Arabi Y, Keenan S, Kumar A, Kumar A. Non-pulmonary infections but not specific pathogens are associated with increased risk of AKI in septic shock. Intensive Care Med 2014; 40:1080-1088. doi 10.1007/s00134-014-3361-1.

36. Peng Q, Zhang L, Ai Y, Zhang L. Epidemiology of acute kidney injury in intensive care septic patients based on the KDIGO guidelines. Chin Med J (Engl) 2014; 127:1820-1826.

37. Patschan D, Heeg M, Brier M, Brandhorst G, Schneider S, Muller GA, Koziolek MJ. CD4+ lymphocyte adenosine triphosphate--a new marker in sepsis with acute kidney injury? Bmc Nephrol 2014; 15:203. doi 10.1186/1471-2369-15-203.

38. Tu Y, Wang H, Sun R, Ni Y, Ma L, Xv F, Hu X, Jiang L, Wu A, Chen X et al. Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail 2014; 36:1559-1563. doi 10.3109/0886022X.2014.949764.

39. Fan H, Zhao Y, Zhu JH, Song FC. Urine neutrophil gelatinase-associated lipocalcin in septic patients with and without acute kidney injury. Ren Fail 2014; 36:1399-1403. doi 10.3109/0886022X.2014.945184.
40. Cho E, Lee JH, Lim HJ, Oh SW, Jo SK, Cho WY, Kim HK, Lee SY. Soluble CD25 is increased in patients with sepsis-induced acute kidney injury. Nephrology (Carlton) 2014; 19:318-324. doi 10.1111/nep.12230.

41. Terzi I, Papaioannou V, Papanas N, Dragoumanis C, Petala A, Theodorou V, Gioka T, Vargemezis V, Maltezos E, Pneumatikos I. Alpha1-microglobulin as an early biomarker of sepsis-associated acute kidney injury: a prospective cohort study. Hippokratia 2014; 18:262-268.

42. Poukkanen M, Wilkman E, Vaara ST, Pettila V, Kaukonen KM, Korhonen AM, Uusaro A, Hovilehto S, Inkinen O, Laru-Sompa Ret al. Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. Crit Care 2013; 17:R295. doi 10.1186/cc13161.

43. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 2013; 17:R278. doi 10.1186/cc13133.

44. Cardinal-Fernandez P, Ferruelo A, El-Assar M, Santiago C, Gomez-Gallego F, Martin-Pellicer A, Frutos-Vivar F, Penuelas O, Nin N, Esteban Aet al. Genetic predisposition to acute kidney injury induced by severe sepsis. J Crit Care 2013; 28:365-370. doi 10.1016/j.jcrc.2012.11.010.

45. de Geus HR, Fortrie G, Betjes MG, van Schaik RH, Groeneveld AB. Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients. Bmc Nephrol 2013; 14:273. doi 10.1186/1471-2369-14-273.

46. Katagiri D, Doi K, Matsubara T, Negishi K, Hamasaki Y, Nakamura K, Ishii T, Yahagi N, Noiri E. New biomarker panel of plasma neutrophil gelatinase-associated lipocalin
and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care 2013; 28:564-570. doi 10.1016/j.jcrc.2013.01.009.

47. Aydogdu M, Gursel G, Sancak B, Yeni S, Sari G, Tasyurek S, Turk M, Yuksel S, Senes M, Ozis TN. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and Cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers 2013; 34:237-246. doi 10.3233/DMA-130966.

48. Suh SH, Kim CS, Choi JS, Bae EH, Ma SK, Kim SW. Acute kidney injury in patients with sepsis and septic shock: risk factors and clinical outcomes. Yonsei Med J 2013; 54:965-972. doi 10.3349/ymj.2013.54.4.965.

49. Poukkanen M, Vaara ST, Pettila V, Kaukonen KM, Korhonen AM, Hovilehto S, Inkinen O, Laru-Sompa R, Kaminski T, Reinikainen M et al. Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units. Acta Anaesthesiol Scand 2013; 57:863-872. doi 10.1111/aas.12133.

50. Zhao N, Tian H H, Li Zet al.[Risk factors and early diagnosis of acute kidney injury in patients with sepsis][J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013, 25(9): 542-5. doi 10.3760/cma.j.issn.2095-4352.2013.09.009.

51. Payen D, Lukaszewicz AC, Legrand M, Gayet E, Faivre V, Megarbane B, Azoulay E, Fieux F, Charron D, Loiseau P et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. Plos One 2012; 7:e35838. doi 10.1371/journal.pone.0035838.

52. Frank AJ, Sheu CC, Zhao Y, Chen F, Su L, Gong MN, Bajwa E, Thompson BT, Christiani DC. BCL2 genetic variants are associated with acute kidney injury in septic shock*. Crit Care Med 2012; 40:2116-2123. https://doi.org/10.1097/CCM.0b013e3182514bca.

53. Plataki M, Kashani K, Cabello-Garza J, Maldonado F, Kashyap R, Kor DJ, Gajic O, Cartin-Ceba R. Predictors of acute kidney injury in septic shock patients: an
observational cohort study. Clin J Am Soc Nephrol 2011; 6:1744-1751. doi 10.2215/CJN.05480610.

54. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010; 36:1333-1340. doi 10.1007/s00134-010-1887-4.

55. Yang, R.L., X.T. Wang and D.W. Liu, [The hemodynamic characteristic and prognosis significance of acute kidney injury caused by septic shock]. Zhonghua Nei Ke Za Zhi 2009; 48(9):715-9.

56. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, Antunes F, Prata MM. Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis 2009; 13:176-181. doi 10.1016/j.ijid.2008.05.1231.

57. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009; 35:871-881. doi 10.1007/s00134-008-1367-2.

58. Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care 2008; 12:R47. doi 10.1186/cc6863.

59. Rowe TA, McKoy JM. Sepsis in Older Adults. Infect Dis Clin North Am 2017; 31: 731-742. doi:10.1016/j.idc.2017.07.010

60. Clifford, Kalin M et al. “Challenges with Diagnosing and Managing Sepsis in Older Adults.” Expert review of anti-infective therapy vol 2016; 14(2): 231-41. doi:10.1586/14787210.2016.1135052.

61. Girman CJ, Kou TD, Brodovicz K, Alexander CM, O'Neill EA, Engel S, Williams-Herman DE, Katz L (2012) Risk of acute renal failure in patients with Type 2 diabetes mellitus. Diabet Med 29: 614-621. doi:10.1111/j.1464-5491.2011.03498.x
62. Sathananthan M, Sathananthan A, Jeganathan N. Characteristics and Outcomes of Patients With and Without Type 2 Diabetes Mellitus and Pulmonary Sepsis. J Intensive Care Med 2019:1585820106. doi:10.1177/0885066619833910.

63. Greenberg N, Roberts WL, Bachmann LM, Wright EC, Dalton RN, Zakowski JJ, Miller WG. Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and Jaffe method principles. Clin Chem 2012; 58: 391-401. doi:1373 / clinchem.2011.172288.

64. Hsu RK, Hsu CY. The Role of Acute Kidney Injury in Chronic Kidney Disease. Semin Nephrol 2016; 36: 283-292. doi:10.1016/j.semnephrol.2016.05.005.

65. He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, Sun L, Peng Y, Liu F, Venkatachalam MA et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int 2017; 92: 1071-1083. doi:10.1016/j.kint.2017.06.030.

66. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis 2015; 66:602-612. doi:1053 / j.ajkd.2015.02.338.

67. Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, Naimark D, Oien C, Smith DH, Coresh J et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. Am J Kidney Dis 2015; 66: 591-601. doi:10.1053/j.ajkd.2015.02.337.

68. Che ML, Yan YC, Zhang Y, et al. Analysis of drug-induced acute renal failure in Shanghai. Zhonghua Yi Xue Za Zhi. 2009-03-24 2009;89(11):744-749.

69. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: "The Triple Whammy". Nefrologia. 2015-01-20 2015;35(2):197-206.
Tables

| Author           | Publication year | Country | AKI diagnostic criteria | Sepsis types          | Study period | Research design | NO.aki |
|------------------|-----------------|---------|-------------------------|-----------------------|--------------|-----------------|--------|
| Bu et al.¹²      | 2019            | China   | KDIGO                   | Sepsis and Septic shock | 2015-2017    | Retrospective case-control study | 132/90 |
| Hsu et al.¹³     | 2019            | China   | AKIN                    | Sepsis                | 2012-2016    | Retrospective case-control study | 99/597 |
| Vilander et al.¹⁴| 2019            | Finland | KDIGO                   | Sepsis                | 2011-2012    | Prospective cohort study | 300    |
| Xing et al.¹⁵    | 2019            | China   | KDIGO                   | Septic shock          | 2018.8-2018.11 | Prospective | 29    |
| Authors          | Year | Location | Scoring System | Condition            | Period          | Study Type            | Patients |
|------------------|------|----------|----------------|----------------------|-----------------|-----------------------|----------|
| Moman et al.     | 2018 | USA      | KDIGO          | Septic shock         | 2007-2009       | Retrospective cohort study | 160/73   |
| Zhi et al.       | 2018 | China    | AKIN           | Sepsis               | 2009-2015       | Retrospective case-control study | 315      |
| Zhou et al.      | 2018 | China    | AKIN           | Sepsis               | 2010-2017       | Retrospective case-control study | 405      |
| Costa et al.     | 2018 | Brazil   | KDIGO          | Septic shock         | 2014-2015       | Prospective cohort study | 66       |
| Song et al.      | 2018 | China    | KDIGO          | Sepsis               | 2015-2016       | Prospective cohort study | 52       |
| Hu et al.        | 2018 | China    | RIFLE          | Sepsis               | 2016-2017       | Prospective cohort study | 52       |
| Fatani et al.    | 2018 | Saudi Arabia | RIFLE  | Severe sepsis and Septic shock | 2016-2017 | Prospective cohort study | 127/73   |
| Gameiro et al.   | 2017 | Portugal | KDIGO          | Sepsis and Septic shock | 2008-2014 | Retrospective case-control study | 391      |
| Katayama et      | 2017 | Japan    | KDIGO          | Sepsis               | 2011-2016       | Retrospective cohort study | 163      |
| Authors           | Year | Location | Staging System | Condition                      | Study Type     | Patients |
|------------------|------|----------|----------------|-------------------------------|----------------|----------|
| Vilander et al.  | 2017 | Finland  | KDIGO          | Septic shock                  | Prospective    | 252      |
| Suberviola et al.| 2017 | Spain    | KDIGO          | Septic shock                  | Prospective    | 312      |
| Fisher et al.    | 2017 | Sweden   | KDIGO          | Septic shock                  | Prospective    | 225      |
| Pérez-Fernández et al. | 2017 | USA      | KDIGO          | Severe sepsis and Septic shock | Prospective    | 82/    |
| Pereira et al.   | 2017 | Portugal | REFILE         | Severe sepsis and Septic shock| Retrospective  | 384     |
| Panich et al.    | 2017 | Thailand | AKIN           | Sepsis                        | Prospective    | 79       |
| Su et al.        | 2016 | China    | KDIGO          | Severe sepsis                 | Prospective    | 45       |
| Yilmaz et al.    | 2015 | Turkey   | AKIN           | Severe sepsis                 | Retrospective  | 68       |
| Medeiros et      | 2015 | Japanese | AKIN           | Sepsis                        | Retrospective  | 144     |
| Authors          | Year | Country | Classification | Time Frame   | Study Type          | Number |
|------------------|------|---------|----------------|--------------|---------------------|--------|
| Dai et al.       | 2015 | China   | KDIGO          | Sepsis       | 2012-2014           | Cohort study |
| Sood et al.      | 2014 | Canada  | RIFLE          | Septic shock | 1996-2008          | Cohort study |
| Peng et al.      | 2014 | China   | KDIGO          | Sepsis       | 2008-2011           | Cohort study |
| Patschan et al.  | 2014 | Germany | AKIN           | Sepsis       | -                   | Retrospective case-control study |
| Tu et al.        | 2014 | China   | AKIN           | Sepsis       | 2011-2013           | Cohort study |
| Fan et al.       | 2014 | China   | RIFLE          | Sepsis       | 2012-2014           | Cohort study |
| CHO et al.       | 2014 | Korea   | RIFLE          | Sepsis       | 2010-2011           | Cohort study |
| Terzi et al.     | 2014 | Greece  | RIFLE          | Sepsis       | -                   | Cohort study |
| Poukkanen et al. | 2013 | Finland | KDIGO          | Severe sepsis| 2011-2012          | Retrospective case-control study |
| Study                 | Year | Country   | AKIN/RIFLE | Disease | Time Period | Study Type   | Participants |
|----------------------|------|-----------|------------|---------|-------------|--------------|--------------|
| Legrand et al.        | 2013 | France    | AKIN       | Severe sepsis and Septic shock | 2006-2010 | Prospective cohort study | 69           |
| Cardinal-Fernández et al. | 2013 | Spain     | RIFLE      | Severe sepsis | 2005-2008 | Prospective cohort study | 65           |
| de Geus et al.        | 2013 | Netherlands | AKIN | Sepsis | 2007-2008 | Prospective cohort study | 49/432       |
| Katagiri et al.       | 2013 | Japan     | RIFLE      | Sepsis | 2010-2011 | Prospective cohort study | 24           |
| Aydogdu et al.        | 2013 | Turkey    | RIFLE      | Sepsis | 2008-2010 | Prospective cohort study | 63           |
| Suh et al.            | 2013 | South Korea | RIFLE | Sepsis and Septic shock | 2010 | Retrospective case-control study | 573          |
| Poukkanen et al.      | 2013 | Finland   | KDIGO      | Severe sepsis | 2011-2012 | Retrospective case-control study | 437          |
| Zhao et al.           | 2013 | China     | AKIN       | Sepsis | 2011-2013 | Retrospective case-control study | 90           |
| Study | Year | Country | AKIN/RIFLE | Condition | Time Period | Study Type | Prevalence |
|-------|------|---------|------------|-----------|-------------|------------|------------|
| Payen et al. | 2012 | Brazil | AKIN | Severe sepsis and Septic shock | 2004-2005 | Retrospective | 12¢ |
| Frank et al. | 2012 | USA | AKIN | Septic shock | 1999-2009 | Retrospective | 627 |
| Plataki et al. | 2011 | USA | RIFLE | Septic shock | 2005-2007 | Retrospective | 237 |
| Ma˚rtensson et al. | 2010 | Sweden | RIFLE OR AKIN | Septic shock | | Prospective | 1¢ |
| YANG et al. | 2009 | China | AKIN | Septic shock | 2001-2008 | Retrospective | 12¢ |
| Lopes et al. | 2009 | Portugal | AKIN | Sepsis | 2004-2007 | Retrospective | 99/ |
| Bagshaw et al. | 2009 | Canada, the United States and Saudi Arabia | RIFLE | Septic shock | 1989-2005 | Retrospective | 2917 |
| Bagshaw et al. | 2008 | Australia | RIFLE | Sepsis | 2000-2005 | Retrospective | 14039 |

Table 2. Summary data of all sepsis patients who developed AKI from included studies.
| Comorbidities | C   | No. Studies | Prevalence  | No. Studies | Prevalence  | No. Studies |
|---------------|-----|-------------|-------------|-------------|-------------|-------------|
| Septic AKI    | 47  | 48.73%      | 22 41.98%   | 12 60.47%   | 5           |
|               |     | (27248/5591)| (16399/3906)| (12678/2096)|             |
| Sex(male)     | 44  | 59.70%      | 22 63.68%   | 11 59.64%   | 5           |
|               |     | (5913/9904) | (1380/2167) | (3191/5350) |             |
| Comorbidities |     |             |             |             |             |
| ARDS          | 3   | 47.02%      | 1 81.19%    | 2 43.34%    | -           |
|               |     | (489/1040)  | (82/101)    | (407/939)   |             |
| Hypertension  |     |             |             |             |             |
| Diabetes      | 32  | 27.57%      | 13 20.53%   | 7 26.75%    | 5           |
|               |     | (2248/8155) | (373/1817)  | (1897/7091) |             |
| Stroke        | 4   | 22.79%      | 1 22.33%    | -           | 1           |
|               |     | (67/294)    | (67/300)    |             |             |
| Cancer        | 6   | 18.23%      | -           | 2 18.80%    | 1           |
|               |     | (705/3745)  |             | (650/3458)  |             |
| Chronic kidney| 14  | 16.46%      | 7 15.52%    | 2 45.13%    | 2           |
|               |     | (449/2795)  | (178/1147)  | (102/226)   |             |
| Cardiovascular disease | 11  | 16.30%      | 4 19.47%    | -           | 1           |
|               |     | (2522/15477)| (169/868)   |             |             |
| Condition                  | Count (%) | Count (%) | Count (%) | Count (%) |
|----------------------------|-----------|-----------|-----------|-----------|
| Congestive heart failure   | 7 12.69%  | 2 17.26%  | 4 12.64%  | 1         |
| COPD                       | 17 12.41% | 6 12.69%  | 5 12.99%  | 1         |
| Hepatic failure            | 4 12.16%  | 2 39.76%  | 1 9.90%   | 3         |
| Coronary artery disease    | 8 11.58%  | 4 10.14%  | 2 9.30%   | 1         |
| Systolic heart failure     | 4 11.25%  | 1 8.00%   | 2 14.32%  | 1         |
| Immunosuppression          | 7 10.35%  | 2 12.74%  | 3 15.80%  | 1         |
| Cirrhosis                  | 6 4.71%   | 1 1.73%   | 2 7.50%   | -         |
| Liver disease              | 7 3.74%   | 3 3.57%   | 1 8.73%   | 2         |
| Emergency admission category| 7 50.88%  | 2 50.90%  | 2 41.46%  | 2         |
| Source of infection | Medical admission | Operative admission | Surgical ward |
|---------------------|-------------------|--------------------|--------------|
|                     | (8701/18506)      | (353/1142)         | (3787/21359) |
|                     | (6938/14112)      | (67/300)           | (2375/14388) |
|                     | (1311/3544)       | (58/252)           | (1380/6482)  |

| Source of infection | Pulmonary | Respiratory | Abdominal | Urinary tract | Skin or soft tissue | Unknown | Community |
|---------------------|-----------|-------------|-----------|---------------|---------------------|---------|-----------|
|                     | (1480/3214) | (273/85) | (2152/6971) | (630/5653) | (335/5554) | (100/1662) | (2041/3558) |
|                     | (448/773) | (54/131) | (177/551) | (58/483) | (5/232) | (3/232) | (10/100) |
|                     | (603/1467) | (74/226) | (1253/4450) | (483/4259) | (218/4033) | (73/879) | (1657/2917) |

- 34
### Medications

| Drug          | Acquired | Nosocomial | Acquired |
|---------------|----------|------------|----------|
| Vasopressors  | 7 64.61% | 3 45.04%   | 2 59.38% |
| (1293/2001)   | (100/222)| (513/864)  |          |
| Vasoactive    | 5 63.22% | 2 35.69%   | 1 67.50% |
| (911/1441)    | (131/367)| (108/160)  |          |
| Steroids      | 3 30.80% | 2 38.16%   | -        |
| (85/276)      | (79/207) |            |          |
| Diuretics     | 4 30.77% | -          | 1 39.40% |
| (296/962)     |          | (97/252)   |          |
| ACEI or ARB   | 8 25.62% | 1 18.41%   | 3 24.97% |
| (619/2416)    | (58/315) | (200/801)  |          |
| Stains        | 5 21.77% | -          | 2 24.13% |
| (357/1640)    |          | (118/489)  |          |
| Nsaids        | 9.63%    | 1 16.19%   | 2 11.45% |
| (203/2108)    | (51/315) | (56/489)   |          |
| Bacteria      |          |            |          |
| Gram-negative | 3 17.26% | -          | 1 22.3%  |
| (160/927)     |          | (49/225)   |          |
|                     | Positive | Mechanical ventilation | Renal replacement | Dialysis | Blood transfusion | Organ transplant | Positive blood culture | Bloodstream infection | Smoke history |
|---------------------|----------|------------------------|-------------------|----------|-------------------|-------------------|------------------------|----------------------|--------------|
| Gram-positive bacteria | 4 10.43% | (99/949)               | (4/22)            | (63/225) |
| Invasive treatment   | 23 68.00% | (7167/10539)          | (415/844)        | (5481/7643) |
|                     | 7 49.17%  | (320/810)             | (19/52)          | (12/66)   |
|                     | 6 71.21%  | (5481/7643)           | (12/66)          |           |
|                     | 18.18%    | (3/303)               | (245/6215)       |           |
|                     | 39.51%    | (3259/7876)           | (2836/6612)      |           |
|                     | 7.64%     | (237/3586)            | (216/2917)       |           |
|                     | 6.61%     | (642/1490)            | (291/720)        |           |
Multiorgan dysfunction (≥3)  

|         |     |         |     |         |     |         |
|---------|-----|---------|-----|---------|-----|---------|
|         | 3   | 50.11%  | 1   | 70.48%  | -   | -       |
| mortality | (436/870) | (222/315) |         |         |         |         |

Mortality  

|         |     |         |     |         |     |         |
|---------|-----|---------|-----|---------|-----|---------|
| ICU     | 10  | 45.99%  | 2   | 50.00%  | 4   | 50.47%  |
| mortality | (1989/4325) | (46/92) |         |         |         | (1672/3313) |
| Hospital | 15  | 49.84%  | 7   | 42.17%  | 3   | 55.83%  |
| mortality | (2732/5481) | (245/581) |         |         |         | (1935/3466) |
| 28-day   | 4   | 36.67%  | 1   | 30.61%  | 1   | 71.42%  |
| mortality | (161/439) | (15/49) |         |         |         | (90/126) |
| 90-day   | 5   | 64.66%  | -   | -       | 1   | 58.42%  |
| morality | (2406/3721) |         |         |         |         | (1704/2917) |

COPD: chronic obstructive pulmonary disease  

ACEI or ARB: angiotensin converting enzyme inhibitors or Angiotensin Receptor Blocker  

Supplemental Information Note  

Additional files: Results of meta-analysis of all factors  

Additional files1 Checklist.PRISMA Checklist. (This file was omitted by the authors in this version of the paper)  

Additional files2 Fig.Sex(male)-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.  

Additional files3 Fig.Septic shock-Forest plot and Funnel plot.  

Additional files4 Fig.Positive blood culture-Forest plot, Funnel plot and Sensitivity analysis.  

Additional files5 Fig.Smoke history-Forest plot, Sensitivity analysis.  

Additional files6 Fig.Bloodstream infection-Forest plot.  

Additional files7 Fig.Hypertension-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.  

Additional files8 Fig.Diabetes mellitus-Forest plot and Funnel plot.  

Additional files9 Fig.Stroke-Forest plot.
Additional files 10 Fig. Cancer-Forest plot.
Additional files 11 Fig. Chronic kidney disease-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.
Additional files 12 Fig. Cardiovascular Diseases-Forest plot, Funnel plot.
Additional files 13 Fig. Congestive heart failure-Forest plot, Funnel plot and Sensitivity.
Additional files 14 Fig. COPD-Forest map, Funnel plot, Sensitivity and Subgroup analysis.
Additional files 15 Fig. Coronary artery disease-Forest plot and Funnel plot.
Additional files 16 Fig. Systolic heart failure-Forest plot, Sensitivity analysis.
Additional files 17 Fig. Immunosuppression-Forest plot, Funnel plot and Sensitivity analysis.
Additional files 18 Fig. Liver disease-Forest plot and Sensitivity analysis.
Additional files 19 Fig. Pulmonary infection-Forest plot, Funnel plot, Sensitivity and subgroup analysis.
Additional files 20 Fig. Abdominal infection-Forest plot, Funnel plot and Sensitivity analysis.
Additional files 21 Fig. Urinary tract infection-Forest plot, and Funnel plot, Sensitivity and Subgroup analysis.
Additional files 22 Fig. Unknown source of infection-Forest plot.
Additional files 23 Fig. Vasopressors-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.
Additional files 24 Fig. Vasoactive drugs-Forest plot and Sensitivity analysis.
Additional files 25 Fig. Diuretic-Forest plot.
Additional files 26 Fig. ACEI or ARB-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.
Additional files 27 Fig. Stains-Forest plot.
Additional files 28 Fig. Gram-negative bacteria-Forest plot.
Additional files 29 Fig. Gram-positive bacteria-Forest plot and Sensitivity analysis.
Additional files 30 Fig. Mechanical ventilation-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.
Additional files 31 Fig. Organ transplant-Forest plot and Sensitivity analysis.
Additional files 32 Fig. Blood transfusion-Forest plot, Sensitivity analysis.

Figures
Flow diagram showing search strategy and study selection. The diagram shows the numbers of titles and studies reviewed in preparation of this meta-analysis of development of acute kidney injury in sepsis patients. n represents the number of studies included in data syntheses. 8 included ‘other’ article represent that the study subjects included at least two of three sepsis (sepsis, septic shock and severe sepsis)
Figure 2

Meta-analysis of risk factors of AKI.
Figure 3

Forest plot for meta-analysis of the association of male sex and AKI.
Funnel plot to detect publication bias for male sex, Egger test, $P=0.32$. 

Figure 4
| Subgroup Variables          | OR (95%CI)       | Forest plot | $\chi^2$ | P - Value | $\bar{p}$ |
|-----------------------------|------------------|-------------|---------|-----------|-----------|
| **Area**                    |                  |             |         |           |           |
| China                       | 1.82 (1.08-2.49) |             | 7.56    | 0.11      | 47.10%    |
| Other country               | 0.61 (0.50-0.74) |             | 28.08   | 0.04      | 48.70%    |
| **Sepsis diagnostic criteria** |                |             |         |           |           |
| Sepsis 3.0                  | 0.89 (0.45-1.76) |             | 1.85    | 0.17      | 46.00%    |
| Sepsis 2.0                  | 1.37 (0.73-2.57) |             | 29.26   | 0.00      | 82.90%    |
| Sepsis 1.0                  | 0.58 (0.47-0.72) |             | 22.34   | 0.01      | 55.20%    |
| **AKI diagnostic criteria** |                  |             |         |           |           |
| KDIGO                       | 0.59 (0.50-0.69) |             | 4.58    | 0.47      | 0.00%     |
| AKIN                        | 0.85 (0.53-1.35) |             | 49.80   | 0.00      | 83.90%    |
| RIFLE                       | 1.01 (0.48-2.11) |             | 11.25   | 0.01      | 73.40%    |
| **Sepsis types**            |                  |             |         |           |           |
| Sepsis                      | 1.13 (0.61-2.08) |             | 42.00   | 0.00      | 83.40%    |
| Septic shock                | 0.59 (0.42-0.82) |             | 12.07   | 0.02      | 56.90%    |
| Severe sepsis               | 0.85 (0.52-0.81) |             | 1.67    | 0.43      | 0.00%     |
| Severe sepsis and septic shock | 0.59 (0.40-0.86) |         | 1.50    | 0.47      | 0.00%     |
| **Research design**         |                  |             |         |           |           |
| Case-control study          | 0.96 (0.43-2.14) |             | 31.10   | 0         | 93.60%    |
| Prospective cohort study    | 0.80 (0.52-1.22) |             | 36.26   | 0         | 75.20%    |
| Retrospective cohort study  | 0.87 (0.50-0.99) |             | 9.30    | 0.096     | 46.20%    |

**Figure 5**

Subgroup analyzes for meta-analysis of the association of pulmonary infection and AKI.